Modality
Fusion Protein
MOA
PD-L1i
Target
TYK2
Pathway
Cell Cycle
RettFL
Development Pipeline
Preclinical
May 2024
→ Oct 2030
PreclinicalCurrent
NCT06235509
1,708 pts·Rett
2024-05→2026-12·Recruiting
NCT07554337
933 pts·Rett
2024-09→2030-10·Recruiting
2,641 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-259mo awayInterim· Rett
2030-10-224.6y awayInterim· Rett
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2026-12-25 · 9mo away
Rett
Interim
2030-10-22 · 4.6y away
Rett
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06235509 | Preclinical | Rett | Recruiting | 1708 | Safety |
| NCT07554337 | Preclinical | Rett | Recruiting | 933 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |